Aura Biosciences (NASDAQ:AURA) Posts Quarterly Earnings Results, Beats Estimates By $0.08 EPS

Aura Biosciences (NASDAQ:AURA) announced its quarterly earnings data on Monday. The company reported ($0.29) earnings per share for the quarter, beating the consensus estimate of ($0.37) by $0.08, FiscalAI reports.

Aura Biosciences Stock Performance

Shares of AURA stock opened at $6.56 on Monday. The firm has a fifty day simple moving average of $6.54 and a two-hundred day simple moving average of $6.72. Aura Biosciences has a 12 month low of $4.73 and a 12 month high of $9.53. The firm has a market capitalization of $680.30 million, a PE ratio of -3.75 and a beta of 0.41.

Wall Street Analyst Weigh In

Several analysts have recently commented on the company. Wall Street Zen downgraded Aura Biosciences from a “hold” rating to a “sell” rating in a research note on Sunday, August 16th. HC Wainwright cut their price target on Aura Biosciences from $24.00 to $18.00 and set a “buy” rating on the stock in a report on Tuesday, August 11th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Aura Biosciences in a research note on Monday, October 12th. Two investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Hold” and a consensus target price of $17.50.

About Aura Biosciences

Aura Biosciences, Inc (NASDAQ:AURA) is a clinical-stage biotechnology company developing targeted therapies for cancer. The company’s platform is designed to use tumor-targeting virus-like particles to selectively bind to cancer cells and deliver therapeutic payloads, with the goal of treating tumors while limiting damage to surrounding healthy tissue.

Aura’s lead product candidate is AU-011, also known as belzupacap sarotalocan, an investigational therapy being developed for primary choroidal melanoma, a form of eye cancer.